Salomon M.
- Country
- France
- Department
- Service des Maladies du Sang
Research Overview
- Phase II Study of Quadruplet Induction and Consolidation with Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High-Risk Multiple Myeloma
- Phase I Study of OT-A201 in Patients with Relapsed/Refractory Hematological Malignancies or Advanced/Metastatic Solid Tumors
- Pharmacokinetic Comparability Study of Pre- and Post-change Teclistamab in Relapsed/Refractory Multiple Myeloma Patients
Data & Insights
Has run more than one trial at 303 of 466 partner sites.
Specializations
Multiple Myeloma Treatment Innovation
The investigator specializes in evaluating novel therapeutic approaches for multiple myeloma, with particular emphasis on both newly diagnosed and relapsed/refractory cases. Their research encompasses innovative treatment combinations including immunotherapy agents and targeted therapies.
- Novel drug combinations
- CAR T-cell therapy assessment
- Immunomodulatory treatments
Blood Cancer Specialization
Their expertise extends to rare blood disorders including AL amyloidosis and plasma cell leukemia. The investigator focuses on developing treatment strategies for these challenging hematologic conditions.
- Targeted therapies
- Novel treatment protocols
- Disease monitoring approaches
Treatment Optimization Studies
The investigator leads research in optimizing treatment durations and combinations, with particular focus on minimal residual disease assessment and stem cell transplantation strategies in blood cancers.
- Treatment duration studies
- Combination therapy evaluation
- Response assessment protocols
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.